Emergent BioSolutions Secures $22.3 Million Anthrax Vaccine Deal

The company confirmed that the modification activates an option period within its current Pentagon contract. An initial shipment valued at approximately $7.4 million is scheduled for delivery before the end of the year, with the remaining balance of the order expected to be fulfilled throughout 2025.

Paul Williams, head of products business and global government affairs at Emergent, stated that the partnership remains vital for maintaining national biodefense preparedness. BioThrax serves as a core component in protecting service members stationed in environments where anthrax risks are heightened.